Company Performance - Zimmer Biomet reported quarterly earnings of $2.07 per share, exceeding the Zacks Consensus Estimate of $1.98 per share, and showing an increase from $2.01 per share a year ago, resulting in an earnings surprise of +4.55% [1] - The company posted revenues of $2.08 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.59%, and an increase from $1.94 billion year-over-year [2] - Over the last four quarters, Zimmer has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - Zimmer shares have declined approximately 13.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.81 on revenues of $2 billion, and for the current fiscal year, it is $7.95 on revenues of $8.19 billion [7] Industry Context - The Medical - Products industry, to which Zimmer belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Core Insights - ACI Worldwide reported quarterly earnings of $0.35 per share, exceeding the Zacks Consensus Estimate of $0.27 per share, but down from $0.47 per share a year ago, resulting in an earnings surprise of +29.63% [1] - The company achieved revenues of $401.26 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.44% and up from $373.48 million year-over-year [2] - ACI Worldwide has consistently surpassed consensus EPS estimates over the last four quarters [2] Financial Performance - The earnings surprise for the previous quarter was +54.55%, with actual earnings of $0.51 per share against an expected $0.33 [1] - The current consensus EPS estimate for the upcoming quarter is $0.91, with projected revenues of $446.9 million, and for the current fiscal year, the EPS estimate is $2.84 on revenues of $1.71 billion [7] Market Position - ACI Worldwide shares have declined approximately 18.8% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The Zacks Industry Rank places the Computer - Software sector in the top 35% of over 250 Zacks industries, indicating a favorable outlook for stocks in this sector [8] Future Outlook - The company's earnings outlook will be influenced by management's commentary during the earnings call and the trends in earnings estimate revisions [4][5] - ACI Worldwide currently holds a Zacks Rank 2 (Buy), suggesting that the shares are expected to outperform the market in the near future [6]

Core Viewpoint - Talen Energy Corporation reported quarterly earnings of $1.5 per share, significantly exceeding the Zacks Consensus Estimate of a loss of $1.13 per share, and showing a substantial increase from earnings of $0.19 per share a year ago [1][2]. Financial Performance - The earnings surprise for the quarter was +232.74%, with the company previously expected to post earnings of $1.17 per share but actually reporting $0.82, resulting in a surprise of -29.91% [2]. - Talen Energy's revenues for the quarter ended June 2025 were $630 million, surpassing the Zacks Consensus Estimate by 31.07%, compared to $489 million in the same quarter last year [3]. - Over the last four quarters, Talen Energy has exceeded consensus EPS estimates two times and has also topped consensus revenue estimates twice [2][3]. Stock Performance - Talen Energy shares have increased approximately 88% since the beginning of the year, outperforming the S&P 500, which gained 7.9% during the same period [4]. - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [4]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $4.47, with expected revenues of $736.04 million, and for the current fiscal year, the estimate remains at $4.47 with revenues projected at $2.3 billion [8]. - The estimate revisions trend for Talen Energy was favorable ahead of the earnings release, resulting in a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [7]. Industry Context - The Alternative Energy - Other industry, to which Talen Energy belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting that the overall industry outlook may impact stock performance [9].

Core Insights - GoodRx Holdings, Inc. (GDRX) reported revenue of $203.07 million for the quarter ended June 2025, reflecting a 1.2% increase year-over-year, while EPS was $0.09, up from $0.08 in the same quarter last year [1] - The reported revenue fell short of the Zacks Consensus Estimate of $205.18 million, resulting in a surprise of -1.03%, and the EPS also missed the consensus estimate of $0.10 by 10% [1] Financial Performance Metrics - Monthly Active Consumers stood at 6, matching the average estimate from three analysts [4] - Subscription plans totaled 668, slightly below the two-analyst average estimate of 677 [4] - Revenue from prescription transactions was $143.06 million, which was lower than the estimated $148.77 million, marking a -2.5% change year-over-year [4] - Revenue from other sources was $4.56 million, compared to the average estimate of $4.63 million, representing a -15.5% year-over-year change [4] - Revenue from pharma manufacturer solutions reached $34.98 million, exceeding the average estimate of $31.54 million, showing a +32% year-over-year increase [4] - Subscription revenue was reported at $20.46 million, below the estimated $20.93 million, reflecting a -7% change compared to the previous year [4] Stock Performance - GoodRx shares have declined by -9.3% over the past month, contrasting with a +0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Cardlytics reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.16, and an improvement from a loss of $0.15 per share a year ago, resulting in an earnings surprise of +18.75% [1] - The company generated revenues of $63.25 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.86% and down from $69.64 million year-over-year [2] - Cardlytics shares have declined approximately 50.4% year-to-date, contrasting with the S&P 500's gain of 7.1% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $70.3 million, and for the current fiscal year, it is -$0.46 on revenues of $275.2 million [7] - The estimate revisions trend for Cardlytics was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Technology Services industry, to which Cardlytics belongs, is currently ranked in the top 41% of over 250 Zacks industries, suggesting that companies in the top half tend to outperform those in the bottom half by more than 2 to 1 [8]

Core Viewpoint - Green Thumb Industries Inc. reported a quarterly loss of $0.01 per share, missing the Zacks Consensus Estimate of $0.04, and showing a decline from earnings of $0.09 per share a year ago, indicating an earnings surprise of -125.00% [1] Financial Performance - The company posted revenues of $293.26 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.56%, and showing an increase from year-ago revenues of $280.15 million [2] - Over the last four quarters, Green Thumb Industries has not surpassed consensus EPS estimates, but has topped consensus revenue estimates three times [2] Stock Performance - Green Thumb Industries shares have declined approximately 11.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $285.85 million, and for the current fiscal year, it is $0.15 on revenues of $1.14 billion [7] Industry Outlook - The Medical - Products industry, to which Green Thumb Industries belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of the stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Protagonist Therapeutics reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.53, and compared to a loss of $0.50 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $5.55 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 46.67%, while year-ago revenues were $4.17 million [2] - Over the last four quarters, Protagonist Therapeutics has surpassed consensus EPS estimates three times, but the recent earnings surprise was -3.77% [1][2] Stock Movement and Outlook - Protagonist Therapeutics shares have increased by approximately 39.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates for the coming quarter at -$0.60 on revenues of $10.67 million, and for the current fiscal year at -$1.05 on revenues of $116.15 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Protagonist Therapeutics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, which may negatively impact stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that investors should monitor these revisions closely [5]

Financial Performance - Soleno Therapeutics reported a quarterly loss of $0.09 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.53, and an improvement from a loss of $0.57 per share a year ago, representing an earnings surprise of +83.02% [1] - The company posted revenues of $32.66 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.58%, compared to zero revenues a year ago [2] Stock Performance - Soleno Therapeutics shares have increased approximately 81.6% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.49 on revenues of $24.62 million, and for the current fiscal year, it is -$2.13 on revenues of $122.75 million [7] Industry Outlook - The Medical - Drugs industry, to which Soleno Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the company's stock may continue to perform well based on these revisions [5][6]

Core Insights - Intuitive Machines, Inc. (LUNR) is expected to report its second-quarter 2025 results on August 7, prior to market opening, with a history of outperforming earnings estimates in three of the last four quarters, averaging a 57.42% earnings surprise [1]. Group 1: Revenue and Earnings Performance - The second quarter is anticipated to show strong revenue growth driven by lunar payload, data analytics, and data transmission services for NASA and commercial contractors [2]. - Successful completion of the IM-2 mission is expected to contribute to revenue, with payments anticipated in the upcoming quarter, likely resulting in higher revenues reflected in the income statement [3]. - Despite strong revenue generation and higher gross profit from efficient program execution, increased selling, general, and administrative expenses due to investments in infrastructure and technology upgrades may negatively impact earnings [4]. Group 2: Financial Estimates - The Zacks Consensus Estimate for LUNR's second-quarter sales is projected at $68.4 million, representing a 65.2% increase from the same quarter last year [5]. - The consensus estimate for loss is set at six cents per share, indicating a decline from the previous year's loss of five cents [5]. Group 3: Earnings Prediction Model - The current model does not predict a definitive earnings beat for LUNR, with an Earnings ESP of -9.09% and a Zacks Rank of 4 (Sell), suggesting lower chances of outperforming earnings expectations [6][7].

Financial Performance - Nuveen Churchill Direct Lending Corp. reported quarterly earnings of $0.46 per share, matching the Zacks Consensus Estimate, but down from $0.57 per share a year ago [1] - The company posted revenues of $53.13 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2.33% and down from $55.09 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates only once and has topped consensus revenue estimates just once [2][3] Market Performance - Nuveen Churchill Direct Lending Corp. shares have declined approximately 5% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $54.9 million, and for the current fiscal year, it is $1.90 on revenues of $218.2 million [7] - The estimate revisions trend for the company was mixed ahead of the earnings release, which may change following the recent report [6] Industry Context - The Financial - SBIC & Commercial Industry, to which Nuveen Churchill Direct Lending Corp. belongs, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]